中等度から重度の慢性尋常性乾癬患者におけるセクキヌマブの有効性および安全性に関する4年間の延長試験

基本情報

NCT ID

NCT01640951

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

675

治験依頼者名

Novartis

概要

CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of relapse regimen. All subjects who completed the full study treatment period (52 weeks) in the cores studies CAIN457A2304 and CAIN457A2307 were eligible to participate in this extension study. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab was used.

対象疾患

介入

依頼者（Sponsor）